Pegylated Interferon Alfa-2B

Liver Transplantation

Merck Sharp & Dohme LLCPhase 3Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

19 Active assets in the Liver Transplantation cohort.

Asset / Sponsor	Phase	Rating
TACROLIMUS The Second Hospital of Tangshan	Phase 4	BBB
Giapreza University of California, San Francisco	Phase 4	BBB
Equine Atg University Hospital, Toulouse	Phase 4	BB
Everolimus Novartis Pharmaceuticals	Phase 3	BB
Sitagliptin University Health Network, Toronto	Phase 4	BB

View all 35 →

Same molecule, other indications

Pegylated Interferon Alfa-2B is also rated in:

chronic hepatitis C virus infectionDormant

BBB

Indicative ·

78 / 100

chronic hepatitis C virus infectionDormant

BB

Indicative ·

64 / 100

adult T-cell leukemia/lymphomaDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.